Is Transcode Therapeutics Inc halal to invest in?

According to Musaffa's Shariah screening methodology, Transcode Therapeutics Inc (RNAZ) is currently classified as NOT HALAL as of May 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Transcode Therapeutics Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Transcode Therapeutics Inc using these criteria to determine its compliance status.

Can Muslims buy shares of Transcode Therapeutics Inc?

Muslim investors may consider investing in Transcode Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Transcode Therapeutics Inc classified as NOT HALAL?

Musaffa determines the Shariah status of Transcode Therapeutics Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Transcode Therapeutics Inc updated?

The Shariah compliance status of Transcode Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Transcode Therapeutics Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Transcode Therapeutics Inc?

You can check the latest Shariah compliance status of Transcode Therapeutics Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

RNAZ Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: May 11, 2026

Report Source: 2025 Annual Report

Transcode Therapeutics Inc. Stock Analysis RNAZ

United States Health Care Nano Cap Report: 2025 Annual

TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company is headquartered in Boston, Massachusetts and currently employs 12 full-time employees. The company went IPO on 2021-04-28. The company is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The firm is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact.

Key Statistics of Transcode Therapeutics Inc (RNAZ)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$6.56$7.22

Today's Open

$6.99

Volume

6379.00

P/E Ratio (TTM)

52 Week Range

$6.08$20.99

Market Cap

7.21M

Avg. Volume

7700.05

Dividend Yield

Financial Metrics & Statements of Transcode Therapeutics Inc (RNAZ)

FAQ's for Transcode Therapeutics Inc (RNAZ)

According to Musaffa’s Shariah screening methodology, Transcode Therapeutics Inc (RNAZ) is currently classified as NOT HALAL as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.